Nucl Med Mol Imaging.  2024 Jun;58(3):140-146. 10.1007/s13139-024-00846-5.

Annotating the Role of ¹⁸F‑FDG PET/CT in Fibromatoses: A Benign Masquerader of Malignancies—Is It Really an Advantageous Tool?

• Kumar S
• Singh H
• Kaman L
• Nada R
• Mittal B

• KMID: 2556864
• DOI: http://doi.org/10.1007/s13139-024-00846-5

Abstract

Fibromatoses are a heterogeneous group of benign proliferating fibroblasts and myofibroblasts which have a high predilection for recurrence and local invasion, especially deep fibromatoses or desmoid fibromatosis. ¹⁸F-FDG PET/CT, the workhorse of oncological imaging in nuclear medicine, can be employed to figure out the nature and aggressiveness of the lesions and various sites of involvement and to monitor treatment response to systemic therapies like tyrosine kinase inhibitors in case of deep or desmoid fibromatoses which is shown in the current research work.

Keyword

Fibromatosis; ¹⁸F-FDG PET/CT; Response; Tyrosine kinase inhibitors